
Overview
Background
Associate Professor Victoria Atkinson is both a Senior Medical Oncologist and a Principal Investigator for clinical trials in the adjuvant and metastatic setting at the Princess Alexandra Hospital and Greenslopes Private Hospital (in collaboration with Gallipoli Medical Research Foundation). Additionally, she is an Associate Professor with the University of Queensland, Clinical School of Medicine. Associate Professor Atkinson’s research interests are in the field of Oncology, and she has extensive experience in targeted-therapies and immunotherapies. Her main research interests are melanoma and gastro-intestinal oncology. Associate Professor Atkinson is passionate about trying to improve outcome for all patients with advanced melanoma as well as advanced gastro-intestinal cancers.
Associate Professor Atkinson has been involved in the clinical development of the current targeted and immunotherapies in melanoma over the past decade bringing these therapies into clinical practice. She has been involved in advocating for patient access to these therapies for patients in Queensland and Australia from guidelines through to reimbursement policies. These therapies have revolutionised the lives of patients and brought about the longest median overall survival for advanced melanoma. However there still remains significant work to be done in therapy resistant disease and she continues to work with therapies towards overcoming resistance.
In the past 5 years, Associate Professor Atkinson has been an Invited Speaker at 22 national and international meetings including Medical Oncology Group of Australia ASM Immunotherapy Symposium, New Zealand Society for Medical Oncology meeting and the Society for Melanoma Research congress. A/Prof Atkinson has published 82 publications, 31 oral abstracts and 65 posters. Associate Professor Atkinson is actively involved in the research supervision of her basic and advanced trainees, and resident medical officers who demonstrate interest in a project. She has supervised trainees to complete their research projects and supported 6 Australian research poster presentations, and 10 international research poster presentations.
She is passionate and motivated to continue to change practice by bringing clinically important and relevant trials to Queensland and to mentor trainees and junior consultants to continue this tradition.
Availability
- Professor Victoria Atkinson is:
- Available for supervision
Research interests
-
Oncology
-
Melanoma
-
Gastro-intestinal oncology
-
Patient outcomes
Works
Search Professor Victoria Atkinson’s works on UQ eSpace
2020
Journal Article
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Ascierto, Paolo A., Del Vecchio, Michele, Mandalá, Mario, Gogas, Helen, Arance, Ana M., Dalle, Stephane, Cowey, C. Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O., Maio, Michele, Middleton, Mark R., de la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A., Millward, Michael, Khushalani, Nikhil I., Queirolo, Paola, Lobo, Maurice, de Pril, Veerle, Loffredo, John, Larkin, James and Weber, Jeffrey (2020). Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology, 21 (11), 1465-1477. doi: 10.1016/S1470-2045(20)30494-0
Featured
2020
Journal Article
Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients
Aoude, Lauren G., Bonazzi, Vanessa F., Brosda, Sandra, Patel, Kalpana, Koufariotis, Lambros T., Oey, Harald, Nones, Katia, Wood, Scott, Pearson, John V., Lonie, James M., Arneil, Melissa, Atkinson, Victoria, Smithers, B. Mark, Waddell, Nicola and Barbour, Andrew P. (2020). Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. Scientific Reports, 10 (1) 17687, 17687. doi: 10.1038/s41598-020-74956-3
2020
Journal Article
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Dummer, Reinhard, Lebbé, Celeste, Atkinson, Victoria, Mandalà, Mario, Nathan, Paul D., Arance, Ana, Richtig, Erika, Yamazaki, Naoya, Robert, Caroline, Schadendorf, Dirk, Tawbi, Hussein A., Ascierto, Paolo A., Ribas, Antoni, Flaherty, Keith T., Pakhle, Neha, Campbell, Catarina D., Gusenleitner, Daniel, Masood, Aisha, Brase, Jan C., Gasal, Eduard and Long, Georgina V. (2020). Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nature Medicine, 26 (10), 1557-1563. doi: 10.1038/s41591-020-1082-2
2020
Journal Article
The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions
Gebhardt, Christoffer, Ascierto, Paolo, Atkinson, Victoria, Corrie, Pippa, Dummer, Reinhard and Schadendorf, Dirk (2020). The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. European Journal of Cancer, 138, 68-76. doi: 10.1016/j.ejca.2020.07.016
2020
Journal Article
Long-term Follow-up of Standard-Dose Pembrolizumab plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
Carlino, Matteo S., Menzies, Alexander M., Atkinson, Victoria, Cebon, Jonathan S., Jameson, Michael B., Fitzharris, Bernard M., McNeil, Catriona M., Hill, Andrew G., Ribas, Antoni, Atkins, Michael B., Thompson, John A., Hwu, Wen-Jen, Hodi, F. Stephen, Guminski, Alexander D., Kefford, Richard, Wu, Haiyan, Ibrahim, Nageatte, Moreno, Blanca Homet and Long, Georgina V. (2020). Long-term Follow-up of Standard-Dose Pembrolizumab plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clinical Cancer Research, 26 (19), 5086-5091. doi: 10.1158/1078-0432.CCR-20-0177
2020
Journal Article
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Dummer, Reinhard, Hauschild, Axel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Kirkwood, John M., Chiarion Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Lesimple, Thierry, Plummer, Ruth, Dasgupta, Kohinoor, Gasal, Eduard, Tan, Monique, Long, Georgina V. and Schadendorf, Dirk (2020). Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. The New England Journal of Medicine, 383 (12), 1139-1148. doi: 10.1056/NEJMoa2005493
2020
Journal Article
Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report
Hultin, Sebastian, Nahar, Kazi, Menzies, Alexander M., Long, Georgina V., Fernando, Suran L., Atkinson, Victoria, Cebon, Jonathan and Wong, Muh Geot (2020). Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report. BMC Nephrology, 21 (1) 391, 1-9. doi: 10.1186/s12882-020-02044-9
2020
Journal Article
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Dummer, Reinhard, Brase, Jan C., Garrett, James, Campbell, Catarina D., Gasal, Eduard, Squires, Matthew, Gusenleitner, Daniel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Flaherty, Keith, Larkin, James, Robert, Caroline, Kefford, Richard, Kirkwood, John M., Hauschild, Axel, Schadendorf, Dirk and Long, Georgina V. (2020). Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. The Lancet Oncology, 21 (3), 358-372. doi: 10.1016/S1470-2045(20)30062-0
2020
Journal Article
Intratumoural immunotherapies in oncology
Xu, Wen, Atkinson, Victoria G. and Menzies, Alexander M. (2020). Intratumoural immunotherapies in oncology. European Journal of Cancer, 127, 1-11. doi: 10.1016/j.ejca.2019.12.007
2020
Journal Article
Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma
Mason, Robert, Dearden, Helen C., Nguyen, Bella, Oon, Jennifer S., Smith, Jessica Louise, Randhawa, Manreet, Mant, Andrew, Warburton, Lydai, Lo, Serigne, Meniawy, Tarek, Guminski, Alexander, Parente, Phillip, Ali, Sayed, Haydon, Andrew, Long, Georgina V., Carlino, Matteo S., Millward, Michael, Atkinson, Victoria G. and Menzies, Alexander M. (2020). Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. Pigment Cell and Melanoma Research, 33 (2) pcmr.12831, 358-365. doi: 10.1111/pcmr.12831
2020
Journal Article
Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial
Eggermont, Alexander M. M., Kicinski, Michal, Blank, Christian U., Mandala, Mario, Long, Georgina V., Atkinson, Victoria, Dalle, Stéphane, Haydon, Andrew, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, Van Den Eertwegh, Alfonsus J. M., Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, Lorigan, Paul C., Krepler, Clemens, Ibrahim, Nageatte, Marreaud, Sandrine, Van Akkooi, Alexander, Robert, Caroline and Suciu, Stefan (2020). Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncology, 6 (4), 519-527. doi: 10.1001/jamaoncol.2019.5570
2020
Journal Article
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆
Owen, C. N., Shoushtari, A. N., Chauhan, D., Palmieri, D. J., Lee, B., Rohaan, M. W., Mangana, J., Atkinson, V., Zaman, F., Young, A., Hoeller, C., Hersey, P., Dummer, R., Khattak, M. A., Millward, M., Patel, S. P., Haydon, A., Johnson, D. B., Lo, S., Blank, C. U., Sandhu, S., Carlino, M. S., Larkin, J. M.G., Menzies, A. M. and Long, G. V. (2020). Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆. Annals of Oncology, 31 (8), 1075-1082. doi: 10.1016/j.annonc.2020.04.471
2020
Journal Article
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
Bhave, Prachi, Pallan, Lalit, Long, Georgina V., Menzies, Alexander M., Atkinson, Victoria, Cohen, Justine V., Sullivan, Ryan J., Chiarion-Sileni, Vanna, Nyakas, Marta, Kahler, Katharina, Hauschild, Axel, Plummer, Ruth, Trojaniello, Claudia, Ascierto, Paolo A., Zimmer, Lisa, Schadendorf, Dirk, Allayous, Clara, Lebbe, Celeste, Maurichi, Andrea, Santinami, Mario, Roy, Severine, Robert, Caroline, Lesimple, Thierry, Patel, Sapna, Versluis, Judith M., Blank, Christian U., Khattak, Adnan, Van der Westhuizen, Andre, Carlino, Matteo S. ... Haydon, Andrew (2020). Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. British Journal of Cancer, 124 (3), 574-580. doi: 10.1038/s41416-020-01121-y
2020
Journal Article
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: Analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)
Atkinson, Victoria, Sandhu, Shahneen, Hospers, Geke, Long, Georgina V., Aglietta, Massimo, Ferrucci, Pier F., Tulyte, Skaiste, Cappellini, Gian Carlo Antonini, Soriano, Virtudes, Ali, Sayed, Poprach, Alexandr, Cesas, Alvydas, Rodriguez-Abreu, Delvys, Lau, Mike, De Jong, Egbert, Legenne, Philippe, Stein, Dara, King, Brianna and Van Thienen, Johannes V. (2020). Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: Analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). Melanoma Research, 30 (3), 261-267. doi: 10.1097/CMR.0000000000000654
2019
Journal Article
Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program
Martin-Algarra, Salvador, Hinshelwood, Rebecca, Mesnage, Soizick, Cebon, Jonathan, Ferrucci, Pier Francesco, Aglietta, Massimo, Neyns, Bart, Chiarion-Sileni, Vanna, Lindsay, Colin R., Del Vecchio, Michele, Linardou, Helen, Merelli, Barbara, Tonini, Giuseppe, Atkinson, Victoria, Freivogel, Klaus, Stein, Dara, Dalland, Lindi, Lau, Mike, Legenne, Philippe, Queirolo, Paola and Millward, Michael (2019). Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program. Melanoma Research, 29 (5), 527-532. doi: 10.1097/CMR.0000000000000608
2019
Journal Article
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies
Pires da Silva, Ines, Glitza, Isabella C., Haydu, Lauren E., Johnpulle, Romany, Banks, Patricia D., Grass, George D., Goldinger, Simone M. A., Smith, Jessica L., Everett, Ashlyn S., Koelblinger, Peter, Roberts-Thomson, Rachel, Millward, Michael, Atkinson, Victoria G., Guminski, Alexander, Kapoor, Rony, Conry, Robert M., Carlino, Matteo S., Wang, Wei, Shackleton, Mark J., Eroglu, Zeynep, Lo, Serigne, Hong, Angela M., Long, Georgina V., Johnson, Douglas B. and Menzies, Alexander M. (2019). Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell and Melanoma Research, 32 (4), 553-563. doi: 10.1111/pcmr.12775
2019
Journal Article
Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature
Xu, Wen, Moor, Rebecca J., Walpole, Euan T. and Atkinson, Victoria G. (2019). Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature. Melanoma Research, 29 (3), 333-337. doi: 10.1097/CMR.0000000000000586
2019
Journal Article
Reply to E. Hindié and K.R. Hess
Long, Georgina V., Dummer, Reinhard, Schadendorf, Dirk, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Lesimple, Thierry, Plummer, Ruth, Dasgupta, Kohinoor, Haas, Tomas, Shilkrut, Mark, Gasal, Eduard, Kefford, Richard, Kirkwood, John M. and Hauschild, Axel (2019). Reply to E. Hindié and K.R. Hess. Journal of Clinical Oncology, 37 (15), 1356-1358. doi: 10.1200/JCO.19.00004
2019
Journal Article
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Schadendorf, Dirk, Hauschild, Axel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Lesimple, Thierry, Plummer, Ruth, Schachter, Jacob, Dasgupta, Kohinoor, Manson, Stephanie, Koruth, Roy, Mookerjee, Bijoyesh, Kefford, Richard, Dummer, Reinhard, Kirkwood, John M. and Long, Georgina V. (2019). Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. The Lancet Oncology, 20 (5), 701-710. doi: 10.1016/S1470-2045(18)30940-9
2019
Conference Publication
Patterns of response for combination of PV-10 oncolytic immunotherapy and checkpoint inhibition
Agarwala, Sanjiv S., Ross, Merrick I., Zager, Jonathan, Shirai, Keisuki, Essner, Richard, Smithers, Bernard M., Atkinson, Victoria, Sarson, David and Wachter, Eric A. (2019). Patterns of response for combination of PV-10 oncolytic immunotherapy and checkpoint inhibition. LONDON: BMC.
Supervision
Availability
- Professor Victoria Atkinson is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Media
Enquiries
For media enquiries about Professor Victoria Atkinson's areas of expertise, story ideas and help finding experts, contact our Media team: